Explore more publications!
Money, Banking & Me
Got News to Share?

Money, Banking & Me: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Money, Banking & Me.

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

December 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31

January 2026

Mo Tu We Th Fr Sa Su
1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31

Press releases published on December 6, 2025

The coldest Ride on Earth: Why Mongolia is the ultimate Winter Destination for Adventurers
December 6, 2025

The coldest Ride on Earth: Why Mongolia is the ultimate Winter Destination for Adventurers

Indeterminate EIN Presswire
Seven Corbett Announces Exclusive 2026 New Year Trip Package in Jim Corbett
December 6, 2025

Seven Corbett Announces Exclusive 2026 New Year Trip Package in Jim Corbett

Indeterminate EIN Presswire
Oriental Artisan Elevates Corporate Gifting with Curated Collection of Handcrafted Eastern Treasures
December 6, 2025

Oriental Artisan Elevates Corporate Gifting with Curated Collection of Handcrafted Eastern Treasures

Indeterminate EIN Presswire
ARH Global Advisors Releases 2026 Manhattan Probate & Trust Real Estate Market Outlook
December 6, 2025

ARH Global Advisors Releases 2026 Manhattan Probate & Trust Real Estate Market Outlook

Indeterminate EIN Presswire
CRMT Investor News: If You Have Suffered Losses in America’s Car-Mart, Inc. (NASDAQ: CRMT), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
December 6, 2025

CRMT Investor News: If You Have Suffered Losses in America’s Car-Mart, Inc. (NASDAQ: CRMT), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Indeterminate GlobeNewswire
Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
December 6, 2025

Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting

Indeterminate GlobeNewswire
TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
December 6, 2025

TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition

Indeterminate GlobeNewswire
DXCM DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages DexCom, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – DXCM
December 6, 2025

DXCM DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages DexCom, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – DXCM

Indeterminate GlobeNewswire
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Sprouts Farmers Market, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SFM
December 6, 2025

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Sprouts Farmers Market, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SFM

Indeterminate GlobeNewswire
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Jayud Global Logistics Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - JYD
December 6, 2025

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Jayud Global Logistics Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - JYD

Indeterminate GlobeNewswire
BioNTechs und OncoC4s selektiver Treg-Modulatorkandidat Gotistobart erzielte klinisch relevanten Gesamtüberlebensvorteil bei Patientinnen und Patienten mit zuvor behandeltem Plattenepithelkarzinom der Lunge
December 6, 2025

BioNTechs und OncoC4s selektiver Treg-Modulatorkandidat Gotistobart erzielte klinisch relevanten Gesamtüberlebensvorteil bei Patientinnen und Patienten mit zuvor behandeltem Plattenepithelkarzinom der Lunge

Indeterminate GlobeNewswire
BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer
December 6, 2025

BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer

Indeterminate GlobeNewswire
Geekstake Reviews Risk Signals Across Multi-Chain Networks in Response to Global Economic Uncertainty
December 6, 2025

Geekstake Reviews Risk Signals Across Multi-Chain Networks in Response to Global Economic Uncertainty

Indeterminate GlobeNewswire
Evaxion presents new data for EVX-04, a cancer vaccine candidate for acute myeloid leukemia at ASH Annual Meeting
December 6, 2025

Evaxion presents new data for EVX-04, a cancer vaccine candidate for acute myeloid leukemia at ASH Annual Meeting

Indeterminate GlobeNewswire
Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025
December 6, 2025

Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025

Indeterminate GlobeNewswire
THE EFFICIENCY PARADOX: 5 Market Anomalies Trading Below Reality
December 6, 2025

THE EFFICIENCY PARADOX: 5 Market Anomalies Trading Below Reality

Indeterminate GlobeNewswire
MLTX 9-DAY DEADLINE ALERT: MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman
December 6, 2025

MLTX 9-DAY DEADLINE ALERT: MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman

Indeterminate GlobeNewswire
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger—TBHC, BLFY, SOUL, and SNCR
December 6, 2025

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger—TBHC, BLFY, SOUL, and SNCR

Indeterminate GlobeNewswire
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger—WBD, TRUE, CMA, and FITB
December 6, 2025

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger—WBD, TRUE, CMA, and FITB

Indeterminate GlobeNewswire
ATYR Lawsuit: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure
December 6, 2025

ATYR Lawsuit: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions